PT - JOURNAL ARTICLE AU - Richardson, Marcy E. AU - Holdren, Megan AU - Brannan, Terra AU - de la Hoya, Miguel AU - Spurdle, Amanda B. AU - Tavtigian, Sean V. AU - Young, Colin C. AU - Zec, Lauren AU - Hiraki, Susan AU - Anderson, Michael J. AU - Walker, Logan C. AU - McNulty, Shannon AU - Turnbull, Clare AU - Tischkowitz, Marc AU - Schon, Katherine AU - Slavin, Thomas AU - Foulkes, William D. AU - Cline, Melissa AU - Monteiro, Alvaro N. AU - Pesaran, Tina AU - Couch, Fergus J. TI - Specifications of the ACMG/AMP variant curation guidelines for the analysis of germline <em>ATM</em> sequence variants AID - 10.1101/2024.05.28.24307502 DP - 2024 Jan 01 TA - medRxiv PG - 2024.05.28.24307502 4099 - http://medrxiv.org/content/early/2024/05/29/2024.05.28.24307502.short 4100 - http://medrxiv.org/content/early/2024/05/29/2024.05.28.24307502.full AB - The ClinGen Hereditary Breast, Ovarian and Pancreatic Cancer (HBOP) Variant Curation Expert Panel (VCEP) is composed of internationally recognized experts in clinical genetics, molecular biology and variant interpretation. This VCEP made specifications for ACMG/AMP guidelines for the ataxia telangiectasia mutated (ATM) gene according to the Food and Drug Administration (FDA)-approved ClinGen protocol. These gene-specific rules for ATM were modified from the American College of Medical Genetics and Association for Molecular Pathology (ACMG/AMP) guidelines and were tested against 33 ATM variants of various types and classifications in a pilot curation phase. The pilot revealed a majority agreement between the HBOP VCEP classifications and the ClinVar-deposited classifications. Six pilot variants had conflicting interpretations in ClinVar and reevaluation with the VCEP’s ATM-specific rules resulted in four that were classified as benign, one as likely pathogenic and one as a variant of uncertain significance (VUS) by the VCEP, improving the certainty of interpretations in the public domain. Overall, 28 the 33 pilot variants were not VUS leading to an 85% classification rate. The ClinGen-approved, modified rules demonstrated value for improved interpretation of variants in ATM.Competing Interest StatementMA and SN were a paid employee of Invitae. MER, TB, TP, CCY, and were paid employees of Ambry Genetics. LZ was a paid employee of Natera. SH was a paid employee of GeneDx.Funding StatementThis study was funded by the National Institutes of Health U24CA258058Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript